Search results for "Pancreatic Ductal"

showing 10 items of 64 documents

PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: A expression patterns and clinical implications

2018

Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that this difference could be due to the immune response to the tumor, and as such, we investigated the expression of PD-1, PD-L1, and CD163 in a series of UCOGC. To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extrapancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic carcinomas were immunostained using antibodies against PD-1, PD-L1, and CD163. In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17 (63%) o…

Male0301 basic medicineIndianaProgrammed Cell Death 1 ReceptorOsteoclast; PDAC; Pancreatic Cancer; Tumor-Associated Macrophages; UCOGCOsteoclastsGiant CellsB7-H1 Antigen0302 clinical medicineTumor-Associated MacrophagesTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]LymphocytesAged 80 and overbiologyTumor-associated macrophagesCell DifferentiationMiddle AgedOsteoclast; Pancreatic cancer; PDAC; Tumor-associated macrophages; UCOGC; 2734ImmunohistochemistryEuropePhenotypemedicine.anatomical_structure030220 oncology & carcinogenesisOsteoclastFemaleAntibodyCarcinoma Pancreatic DuctalAdult2734Antigens Differentiation MyelomonocyticReceptors Cell SurfaceUCOGCPathology and Forensic MedicinePancreatic Cancer03 medical and health sciencesImmune systemAll institutes and research themes of the Radboud University Medical CenterAntigens CDOsteoclastPD-L1Pancreatic cancerBiomarkers TumormedicineHumansHistiocyteAgedNeoplasm StagingPDACHistiocytesPancreatic cancermedicine.diseasePancreatic Neoplasms030104 developmental biologyGiant cellCancer researchbiology.proteinCD163
researchProduct

Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin

2016

BACKGROUND: High Neutrophil/Lymphocyte ratio (NLR), as a measure of enhanced inflammatory response, has been negatively associated with prognosis in patients with localized pancreatic ductal adenocarcinoma (PDA). OBJECTIVE: In the present study, we aimed at investigating the prognostic value of NLR in two homogeneous groups of chemotherapy-na've metastatic PDA patients. Patients were treated with either gemcitabine (GEM) or gemcitabine/ oxaliplatin (GEMOXA). We also assessed whether NLR could identify patients benefiting from the use of oxaliplatin. METHODS: Consecutive PDA patients treated at the Medical Oncology Unit of Tor Vergata University Hospital of Rome with either GEM or GEMOXA wer…

Male0301 basic medicineOncologyCancer ResearchNeutrophil/lymphocyte ratio; gemcitabine; oxaliplatin; pancreatic ductal adenocarcinomaOrganoplatinum CompoundsNeutrophilsSettore MED/06 - Oncologia MedicaLymphocyteAntineoplastic AgentLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsLymphocytesNeoplasm MetastasisAged 80 and overNeutrophilPancreatic NeoplasmgemcitabineGeneral MedicineMiddle AgedPrognosisNeoplasm MetastasiTreatment Outcomemedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioLymphocyteFemaleHumanCarcinoma Pancreatic Ductalmedicine.drugAdultmedicine.medical_specialtyPancreatic ductal adenocarcinomaPrognosiInflammatory responseeducationpancreatic ductal adenocarcinomaAntineoplastic Agents03 medical and health sciencesGeneticNegatively associatedInternal medicineMetastatic pancreatic cancerGeneticsmedicineHumansIn patientAgedProportional Hazards ModelsSettore MED/04 - Patologia GeneraleAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundfungioxaliplatinBiomarkerGemcitabineOxaliplatinPancreatic Neoplasms030104 developmental biologyROC CurveProportional Hazards ModelbusinessBiomarkers
researchProduct

Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer

2020

AbstractImmune suppressing molecule CD73 is overexpressed in various cancers and associated with poor survival. Little is so far known about the predictive value of CD73 in pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to investigate the prognostic significance of CD73 in PDAC. The study material consisted of 110 radically treated patients for PDAC. Tissue microarray blocks were constructed and stained immunohistochemically using CD73 antibody. Staining intensity and numbers of stained tumour cells, inflammatory cells, stroma, and blood vessels were assessed. High-level CD73 expression in tumour cells was positively associated with PD-L1 expression, perineural invas…

Male0301 basic medicinePathologyentsyymitDatabases Factualpancreatic cancerPerineural invasionB7-H1 Antigen0302 clinical medicineRisk FactorsTumor MicroenvironmentMedicine5'-NucleotidasehaimasyöpäAged 80 and overTissue microarraybiologyGeneral MedicineMiddle AgedPrognosisTreatment OutcomesyöpäsolutChemotherapy AdjuvantimmuunijärjestelmäLymphatic Metastasis030220 oncology & carcinogenesisOriginal ArticleFemaleAntibodyCarcinoma Pancreatic DuctalPD-L1Cell typemedicine.medical_specialtyMicroenvironmentGPI-Linked ProteinsRisk AssessmentPancreaticoduodenectomyPathology and Forensic Medicine03 medical and health sciencesLymphocytes Tumor-InfiltratingPancreatectomyImmune systemStromaPancreatic cancerPD-L1Biomarkers TumorHumansMolecular BiologyAgedNeoplasm Stagingbusiness.industryennusteetPancreatic cancerCell Biologymedicine.disease3126 Surgery anesthesiology intensive care radiologymicroenvironmentPancreatic Neoplasms030104 developmental biologybiology.proteinCD73prognosisNeoplasm Gradingbusiness
researchProduct

Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to pre…

2014

Background Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of patients with PDAC, with well-defined clinical-pathological features. Methods mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients treated with gemcitabine after surgical tumor resection. To detect possible interaction between gene expression levels and to identify subgroups of patients a…

MaleOncologyCHOPEquilibrative nucleoside transporter 1BioinformaticsDeoxycytidineCohort StudiesPancreatic ductal adenocarcinomachemistry.chemical_compoundMedicine(all)Transcription Factor CHOPbiologyDCKGeneral MedicineMiddle AgedSurvival RateDisease ProgressionAdenocarcinomaFemaleMRP1DeoxycytidineMultidrug Resistance-Associated ProteinsCarcinoma Pancreatic Ductalmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaMalignancyhENT1General Biochemistry Genetics and Molecular BiologyEquilibrative Nucleoside Transporter 1Internal medicinemedicineHumansRNA MessengerSurvival rateAgedBiochemistry Genetics and Molecular Biology(all)business.industryResearchRECPAMmedicine.diseaseGemcitabineGemcitabinechemistrybiology.proteinPancreatic ductal adenocarcinoma hENT1 CHOP MRP1 DCK RECPAMbusinessTranscription Factor CHOPCHOP
researchProduct

Osteoclast-like Giant Cell Tumor of the Pancreas With Ductal Adenocarcinoma: Case Report with Novel Data on Histogenesis

2002

MalePathologymedicine.medical_specialtyPancreatic diseaseEndocrinology Diabetes and MetabolismCathepsin KOsteoclastsBiologyHistogenesisCathepsin BEndocrinologyImmunophenotypingOsteoclastInternal MedicinemedicineHumansPancreatic ductHepatologyGiant Cell TumorsOsteoclast-Like Giant CellMiddle Agedmedicine.diseaseCathepsinsImmunohistochemistryPancreatic Neoplasmsmedicine.anatomical_structureAdenocarcinomaPancreasCarcinoma Pancreatic DuctalPancreas
researchProduct

Late postpancreatectomy hemorrhage after pancreaticoduodenectomy: is it possible to recognize risk factors ?

2012

Context Post-pancreatectomy hemorrhage is one of the most common complications after pancreaticoduodenectomy. Objective To evaluate the late post-pancreatectomy hemorrhage rate according to the International Study Group of Pancreatic Surgery criteria and to recognize factors related to its onset. Methods A prospective study of 113 patients who underwent pancreaticoduodenectomy was conducted. Late post-pancreatectomy hemorrhage was defined according to the criteria of the International Study Group of Pancreatic Surgery. Demographic, clinical, surgical and pathological data were considered and related to late post-pancreatectomy hemorrhage. Results Thirty-one (27.4%) patients had a post-pancr…

MaleTime FactorsIncidencePancreatectomy Hemorrhage Pancreatic FistulaHemorrhageComorbidityMiddle AgedCarcinoma NeuroendocrinePancreatic NeoplasmsAdenocarcinoma PapillaryPancreatic FistulaSettore MED/18 - Chirurgia GeneralePancreatectomyPostoperative ComplicationsRisk FactorsPancreatitis ChronicHumansFemaleProspective StudiespancreaticoduodenectomyAgedCarcinoma Pancreatic Ductal
researchProduct

Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets?

2015

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and few chemotherapeutic choices. MicroRNAs (miRNAs) are non-coding, single-stranded RNAs of around 22 nucleotides involved in the pathogenic mechanisms of carcinogenesis and metastasis. They have been studied in many tumors in order to identify potential diagnostic, prognostic or therapeutic targets. In the current literature, many studies have analyzed the role of miRNAs in PDAC. In fact, the absence of appropriate biomarkers, the difficultly of early detection of this tumor, and the lack of effective chemotherapy in patients with unresectable disease have focused attention on miRNAs as new, i…

Maleendocrine system diseasesPrognosiSettore MED/06 - Oncologia MedicaMice NudeReviewDiseaseAdenocarcinomaMalignancymedicine.disease_causeMetastasisMicemicroRNABiomarkers TumorCarcinomamedicineAnimalsHumansmiRNAbiomarkers; miRNAs; pancreatic adenocarcinoma; prognosis; therapyAnimalbusiness.industryPancreatic NeoplasmbiomarkersMicroRNABiomarkerPrognosismedicine.diseasePhenotypedigestive system diseasesPancreatic NeoplasmsGene Expression Regulation NeoplasticMicroRNAsPhenotypeBiomarkers; miRNAs; Pancreatic adenocarcinoma; Prognosis; Therapy; Adenocarcinoma; Animals; Biomarkers Tumor; Carcinoma Pancreatic Ductal; Female; Gene Expression Regulation Neoplastic; Humans; Male; Mice; Mice Nude; MicroRNAs; Pancreatic Neoplasms; Phenotype; Prognosis; OncologyOncologymiRNAsImmunologyCancer researchAdenocarcinomaFemaleTherapybusinessCarcinogenesisPancreatic adenocarcinomaCarcinoma Pancreatic DuctalHuman
researchProduct

Imaging features of pancreatic metastases: A comparison with pancreatic ductal adenocarcinoma

2018

Purpose: To compare imaging features of pancreatic metastases (PM) with those of pancreatic ductal adenocarcinomas (PDAC). Methods: CT and MR scans of 24 patients with 54 PM and 30 patients with PDAC were reviewed to evaluate the imaging features, which were compared by using a Chi square test. Results: We found a statistically significant difference between PM and PDAC based on location (P < 0.001), margins (P < 0.001), arterial enhancement (P = 0.004), rim enhancement (P < 0.001), pancreatic duct dilatation (P = 0.01), common bile duct dilatation (P = 0.003), vascular involvement (P = 0.02), parenchymal atrophy (P < 0.001), peripancreatic fluid (P = 0.03). Conclusion: Imaging features mig…

Malemedicine.medical_specialtyRadiology Nuclear Medicine and ImagingPancreatic ductal adenocarcinomaLung Neoplasmsendocrine system diseasesMetastaseComputed tomographyAdenocarcinoma030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineHumansAbdominal radiology; Adenocarcinoma; Computed tomography; Magnetic resonance; Metastases; Pancreas; Radiology Nuclear Medicine and ImagingPancreaPancreatic carcinomaCarcinoma Renal CellComputed tomographyAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industrySignificant differenceMagnetic resonance imagingNeoplasms Second PrimaryMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAbdominal radiologydigestive system diseasesKidney NeoplasmsPancreatic Neoplasmsmedicine.anatomical_structureMagnetic resonance030220 oncology & carcinogenesisAdenocarcinomaFemaleRadiologybusinessPancreasTomography X-Ray ComputedCarcinoma Pancreatic Ductal
researchProduct

Impact of structured report on the quality of preoperative CT staging of pancreatic ductal adenocarcinoma: assessment of intra- and inter-reader vari…

2019

Purpose: To evaluate whether a structured radiology report improves the completeness of preoperative CT staging of pancreatic ductal adenocarcinoma (PDA) compared to conventional free-text reports. Methods: We retrospectively included 27 patients (mean age, 64 ± 11.1 years) referred for pancreatic preoperative CT scan for staging of PDA between 2015 and 2018 and in whom a diagnosis of pancreatic adenocarcinoma was ultimately confirmed. Four readers independently reported CT scans with both conventional free-text and structured reports. Differences in reported morphologic and vascular features with the two reports were assessed through McNemar Test. Intra-reader and inter-reader were calcula…

Malemedicine.medical_specialtyStructured ReportingLeft gastric arteryUrologyPancreatic Cancer StagingPancreatic Ductal AdenocarcinomaAdenocarcinomaSplenic artery030218 nuclear medicine & medical imagingGastroduodenal artery03 medical and health sciences0302 clinical medicineMcNemar's testComputed Tomographymedicine.arteryStructured reportingmedicineHumansRadiology Nuclear Medicine and imagingSuperior mesenteric veinAgedNeoplasm StagingRetrospective StudiesAged 80 and overRadiological and Ultrasound Technologybusiness.industryGastroenterologyReproducibility of ResultsMiddle Agedmedicine.diseasePancreatic NeoplasmsSplenic vein030220 oncology & carcinogenesisAdenocarcinomaFemaleRadiologyTomography X-Ray ComputedbusinessCarcinoma Pancreatic Ductal
researchProduct

NUPR1 works against the metabolic stress-induced autophagy-associated cell death in pancreatic cancer cells.

2013

The incidence of pancreatic adenocarcinoma is increasing with more than 43,000 predicted new cases in the US and 65,000 in Europe this year. Pancreatic cancer patients have a short life expectancy with less than 3–4% 5-y survival, which results in an equivalent incidence and mortality rate. One of the major challenges in pancreatic cancer is the identification of pharmacological approaches that overcome the resistance of this cancer to therapy. Intensive research in the past decades has led to the classification of pancreatic cancers and the identification of the driver key genetic events. Despite the advances in understanding the molecular mechanisms responsible for pancreatic cancer patho…

Oncologymedicine.medical_specialtyCell SurvivalDrug resistanceDiseaseBiologyProtein Serine-Threonine KinasesModels BiologicalAurora KinasesStress PhysiologicalPancreatic cancerInternal medicineCarcinomamedicineAutophagyBasic Helix-Loop-Helix Transcription FactorsHumansMolecular BiologyCell DeathMechanism (biology)Mortality rateCancerCell Biologymedicine.diseaseAutophagic PunctumNeoplasm ProteinsEndocrinologyDrug Resistance NeoplasmAdenocarcinomaCarcinoma Pancreatic DuctalAutophagy
researchProduct